FGFR2 Antibody

Catalog Number:

33372

Amount:

100μg

Price:

$319

Swiss-Prot No:

Swiss-Prot: P21802
NCBI Gene ID: 2263

Form of Antibody:

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Storage/Stability:

Immunogen:

Synthesized peptide derived from human FGFR2.

Purification:

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Specificity/Sensitivity:

The antibody detects endogenous levels of total FGFR2 protein.

Applications:

WB IHC

Background:

Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.

Xavier Coumoul, Nucleic Acids Res., Jun 2005; 33: e102.
Nan E. Hatch, J. Biol. Chem., Sep 2006; 281: 27292 - 27305.
Sheri L. Kuslak, Development, Feb 2007; 134: 557 - 565.
Anita Petiot, Development, May 2005; 132: 2441 - 2450.

References:

appl_detail:

Western blotting: 1:500~1:3000
Immunohistochemistry: 1:50~1:100

Datasheet PDF